Takaki Hiwasa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2622029/publications.pdf

Version: 2024-02-01

61	1,043	430874	501196
papers	citations	18 h-index	28 g-index

65	65	65	838
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Serum Anti-BRAT1 is a Common Molecular Biomarker for Gastrointestinal Cancers and Atherosclerosis. Frontiers in Oncology, 2022, 12, .	2.8	5
2	Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma. Esophagus, 2022, 19, 617-625.	1.9	1
3	Antiâ€FIRÎ”exon2 autoantibody as a novel indicator for better overall survival in gastric cancer. Cancer Science, 2021, 112, 847-858.	3.9	5
4	Novel serum autoantibodies against ÃŸ-actin (ACTB) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 388-394.	1.7	11
5	Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Medicine, 2021, 19, 131.	5.5	13
6	Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. Scientific Reports, 2021, 11, 13450.	3.3	14
7	Association of serum levels of antibodies against ALDOA and FH4 with transient ischemic attack and cerebral infarction. BMC Neurology, 2021, 21, 274.	1.8	4
8	Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer. Frontiers in Oncology, 2021, 11, 708039.	2.8	14
9	Identification of serum antiâ€striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers. Molecular and Clinical Oncology, 2021, 15, 237.	1.0	5
10	Serum anti-SERPINE1 antibody as a potential biomarker of acute cerebral infarction. Scientific Reports, 2021, 11, 21772.	3.3	11
11	Serum antiâ€ŁRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Science, 2020, 111, 4453-4464.	3.9	16
12	Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases. Heliyon, 2020, 6, e04661.	3.2	16
13	Circulating Anti-Sorting Nexins 16 Antibodies as an Emerging Biomarker of Coronary Artery Disease in Patients with Obstructive Sleep Apnea. Diagnostics, 2020, 10, 71.	2.6	7
14	Association between serum antiâ€ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension. International Journal of Molecular Medicine, 2020, 46, 1274-1288.	4.0	11
15	Autoantibody in Cancer. , 2019, , 25-40.		1
16	The accuracy of flow cytometric cell-based assay to detect anti-myelin oligodendrocyte glycoprotein (MOG) antibodies determining the optimal method for positivity judgement. Journal of Neuroimmunology, 2019, 336, 577021.	2.3	20
17	Antiâ€<scp>FIR</scp>Î”exon2, a splicing variant form of <scp>PUF</scp>60, autoantibody is detected in the sera of esophageal squamous cell carcinoma. Cancer Science, 2019, 110, 2004-2013.	3.9	14
18	Elevated levels of autoantibodies against EXD2 and PHAX in the sera of patients with chronic thromboembolic pulmonary hypertension. PLoS ONE, 2019, 14, e0211377.	2.5	5

#	Article	IF	Citations
19	Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget, 2018, 9, 5600-5613.	1.8	38
20	Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis. Journal of Neuroimmunology, 2018, 325, 54-60.	2.3	17
21	Elevation of autoantibody level against PDCD11 in patients with transient ischemic attack. Oncotarget, 2018, 9, 8836-8848.	1.8	18
22	Elevation of Autoantibody in Patients with Ischemic Stroke. Neurologia Medico-Chirurgica, 2018, 58, 303-310.	2.2	12
23	Investigation of novel biomarkers for predicting the clinical course in patients with ulcerative colitis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 1975-1983.	2.8	11
24	Circulating autoantibodies against neuroblastoma suppressor of tumorigenicity 1 (NBL1): A potential biomarker for coronary artery disease in patients with obstructive sleep apnea. PLoS ONE, 2018, 13, e0195015.	2.5	12
25	Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library. Oncotarget, 2018, 9, 18559-18569.	1.8	26
26	Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-2-4.	0.0	0
27	Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome. International Journal of Cardiology, 2017, 243, 1-8.	1.7	19
28	Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors. Oncotarget, 2017, 8, 106206-106221.	1.8	5
29	Circulating Anti-Coatomer Protein Complex Subunit Epsilon (COPE) Autoantibodies as a Potential Biomarker for Cardiovascular and Cerebrovascular Events in Patients with Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 2017, 13, 393-400.	2.6	12
30	Elevated Adiponectin Antibody Levels in Sera of Patients with Atherosclerosis-Related Coronary Artery Disease, Cerebral Infarction and Diabetes Mellitus. Journal of Circulating Biomarkers, 2016, 5, 8.	1.3	12
31	Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients. Oncotarget, 2016, 7, 82493-82503.	1.8	25
32	Protein kinase CÎ±-mediated cytotoxic activity of ineupatorolide B from Inula cappa DC. in HeLa cells. International Journal of Oncology, 2015, 47, 1839-1844.	3.3	4
33	Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX). Journal of Translational Medicine, 2015, 13, 71.	4.4	35
34	Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies. Journal of Neuroimmunology, 2015, 284, 30-36.	2.3	28
35	Association of Serum Antibody Levels against TUBB2C with Diabetes and Cerebral Infarction. Gratis Journal of Biomedical Sciences, 2015, 1, .	0.0	10
36	Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas. BMC Cancer, 2014, 14, 452.	2.6	24

#	Article	IF	Citations
37	Impact of serum biomarkers on esophageal squamous cell carcinoma. Esophagus, 2012, 9, 131-140.	1.9	16
38	Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas. Journal of Experimental and Clinical Cancer Research, 2012, 31, 85.	8.6	27
39	Identification of a novel SEREX antigen family, ECSA, in esophageal squamous cell carcinoma. Proteome Science, 2011, 9, 31.	1.7	32
40	Decrease in chemosensitivity against anticancer drugs by an esophageal squamous cell carcinoma SEREX antigen, AISEC. International Journal of Oncology, 2009, 34, 641-8.	3.3	4
41	Identification of Makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma. BMC Cancer, 2009, 9, 232.	2.6	29
42	Activation of NFAT signal by p53â€K120R mutant. FEBS Letters, 2009, 583, 1916-1922.	2.8	15
43	Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer. Journal of Gastroenterology, 2009, 44, 691-696.	5.1	13
44	Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. International Journal of Oncology, 2007, 30, 97.	3.3	17
45	Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. International Journal of Oncology, 2007, 30, 97-103.	3.3	29
46	Sensitization against anticancer drugs by transfection with UBE2I variant gene into ras-NIH3H3 mouse fibroblasts. Anticancer Research, 2007, 27, 3227-33.	1.1	9
47	Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. International Journal of Oncology, 2006, 28, 463.	3.3	8
48	Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Science, 2006, 97, 380-386.	3.9	37
49	Enhancement of chemosensitivity toward peplomycin by calpastatin-stabilized NF-Î²B p65 in esophageal carcinoma cells: possible involvement of Fas/Fas-L synergism. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1025-1037.	4.9	17
50	Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. International Journal of Oncology, 2006, 28, 463-8.	3.3	18
51	Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. International Journal of Cancer, 2004, 112, 1029-1035.	5.1	96
52	Drug-sensitivity pattern analysis for study of functional relationship between gene products. FEBS Letters, 2003, 552, 177-183.	2.8	9
53	Regulation of Transformed State by Calpastatin via PKCÏµ in NIH3T3 Mouse Fibroblasts. Biochemical and Biophysical Research Communications, 2002, 290, 510-517.	2.1	18
54	Decrease in growth factor receptors after treatment with serine protease inhibitor ONO-3403. International Journal of Oncology, 2002, 20, 797-802.	3.3	0

#	Article	IF	Citations
55	Studies on p53 and Bax protein expression in Cockayne syndrome cells after UV irradiation and interferon-? treatment. Cell Biochemistry and Function, 2001, 19, 221-225.	2.9	0
56	Preclinical Study of Adenoviral p53 Gene Therapy for Esophageal Cancer. Surgery Today, 2001, 31, 597-604.	1.5	41
57	Stimulation of ultraviolet-induced apoptosis of human fibroblast UVr-1 cells by tyrosine kinase inhibitors. FEBS Letters, 1999, 444, 173-176.	2.8	43
58	Suppression of okadaic acid-induced apoptosis by overexpression of calpastatin in human UVr-1 cells. FEBS Letters, 1999, 459, 391-394.	2.8	17
59	Down-regulation of protein kinase CÎ± and Î³ and enhanced TPA-induced neurite formation inDAN-transfected neuroblastoma cells. FEBS Letters, 1998, 440, 25-28.	2.8	2
60	Suppression of Transformed Phenotypes of Ha-ras-Transformed NIH3T3 Cells by Caspase-2. Biochemical and Biophysical Research Communications, 1998, 250, 741-746.	2.1	4
61	Cysteine proteinase inhibitors and rasgene products share the same biological activities including tranforming activity toward NIH3T3 mouse fibroblasts and the differentiation-inclucing activity toward PC12 rat pheochromocytoma cells. Carcinogenesis, 1990, 11, 75-80.	2.8	61